Adelis Equity

SSI Diagnostica Group — Unleashing potential of decades of world-class research

Adelis Equity · Adelis Equity

SSI Diagnostica Group is a globally active specialty diagnostics company focusing on rapid tests for gastrointestinal, respiratory, and bloodborne diseases, plus antisera for vaccine manufacturers. Adelis carved out the state-owned entity in 2016 and built a new management team. Key acquisitions: CTK Biotech (2020), Techlab (2022), Gulf Coast Scientific (2025). Grew from ~80 to ~600 employees, €20m to over €110m in sales. 5x growth, 20% annualized.

Healthcare Carve-out Diagnostics M&A
Read case study